Positive Psychology Intervention for Blood Cancer

Phase-Based Progress Estimates
Blood Cancer+2 MorePositive Psychology Intervention - Behavioral
18 - 90
All Sexes
What conditions do you have?

Study Summary

This trial is to see if the PATH program is feasible and acceptable to help improve quality of life for those who have undergone stem cell transplant for blood cancer treatment.

Eligible Conditions
  • Blood Cancers
  • Blood Cancer

Treatment Effectiveness

Study Objectives

2 Primary · 1 Secondary · Reporting Duration: At baseline (registration) and then week 9 (+/- 1 week) and week 18 (+/- 1 week) from the time of registration

Week 18
Mean Coping Score
Mean Fatigue Score
Mean Optimism Score
Mean Overall Function Score
Mean Positive Affect Score
Mean Post Traumatic Stress Disorder Checklist
Mean Quality of Life Scores
Mean Social Support Score
Week 18
Mean Flourishing Score
Mean Gratitude Score
Mean Minutes of Light Activity per Day
Mean Satisfaction Score
Mean Sedentary Leisure Time per Day
Mean Self-Reported Tacrolimus Adherence Score
Week 9
Acceptability Rate
Feasibility Rate
Week 18
Mean Immunosuppressant Adherence Rate

Trial Safety

Trial Design

2 Treatment Groups

Usual Care Control
1 of 2
PATH Intervention
1 of 2

Active Control

Experimental Treatment

70 Total Participants · 2 Treatment Groups

Primary Treatment: Positive Psychology Intervention · No Placebo Group · N/A

PATH Intervention
Experimental Group · 1 Intervention: Positive Psychology Intervention · Intervention Types: Behavioral
Usual Care ControlNoIntervention Group · 1 Intervention: Usual Care Control · Intervention Types:
First Studied
Drug Approval Stage
How many patients have taken this drug
Positive Psychology Intervention

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: at baseline (registration) and then week 9 (+/- 1 week) and week 18 (+/- 1 week) from the time of registration

Who is running the clinical trial?

National Cancer Institute (NCI)NIH
13,068 Previous Clinical Trials
41,129,232 Total Patients Enrolled
Dana-Farber Cancer InstituteLead Sponsor
1,016 Previous Clinical Trials
393,746 Total Patients Enrolled
Hermioni Amonoo, MD, MPPPrincipal InvestigatorDana-Farber Cancer Institute

Eligibility Criteria

Age 18 - 90 · All Participants · 3 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you: